Bias and the safety of people on clozapine

I've just been on the internet doing more research into clozapine.

http://bjp.rcpsych.org/cgi/content/abstract/169/4/483
This abstract has details of research conducted on clozapine and published in a peer reviewed journal.

It's been done at the Clozaril Patient Monitoring Service which is owned by Sandoz Pharmaceuticals, the people who make clozapine.

Sandoz originally voluntarily withdrew clozapine shortly after it was first introduced because of the problems of agranulcytosis which killed approximately 0.35% of people taking it through secondary infections when it was introduced (I guess within a relatively short period).

It was psychiatrists who lobbied for it's reintroduction. It is the best treatment for treatment resistant schizophrenia and suicide in schizophrenia in their eyes. It is by far the best pharmocological 'treatment' for suicide.

To reduce the risk from agranulocytosis blood monitoring is done. This is monitored by the CPMS because every patient on clozapine should be registered here.

The CPMS is owned by Sandoz Pharmaceuticals. There are still a high number of people on clozapine dying prematurely.

There is a problem of bias that exists in all research and in all people. An example of bias might be the results from trials of generic clozapine versus branded Clozaril.

From
http://bjp.rcpsych.org/cgi/content/full/189/2/184
"
Clinical equivalence has also been questioned (Anon, 2001). Five papers reporting on outcomes in a total of 131 patients have been published. One, a case series (Mofsen & Balter, 2001), reported a high relapse rate and one (Kluznik et al, 2001),which was sponsored by the patent holder, reported a trend towards deterioration. These papers have been widely cited as proof that switching patients to generic clozapine is a high-risk strategy. The work of Makela et al (2003) (no sponsorship declared), and also of Sajbel et al (2001) and Stoner et al (2003), both sponsored by a generic manufacturer, did not replicate these findings. This work is less well known.
"